Cover Image
市場調查報告書

細胞週期蛋白依賴性激酶4:開發中產品分析

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 367821
出版日期 內容資訊 英文 112 Pages
訂單完成後即時交付
價格
Back to Top
細胞週期蛋白依賴性激酶4:開發中產品分析 Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2017
出版日期: 2017年11月07日 內容資訊: 英文 112 Pages
簡介

本報告提供以細胞週期蛋白依賴性激酶4為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

細胞週期蛋白依賴性激酶4 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Beta Pharma Inc
  • Eli Lilly and Company
  • FLX Bio Inc
  • G1 Therapeutics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Novartis AG
  • Onconova Therapeutics Inc
  • Pfizer Inc
  • TEIJIN FIBERS製藥
  • Tiziana Life Sciences Plc
  • ViroStatics srl
  • XuanZhu Pharma Co Ltd

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1123TDB

Summary:

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) pipeline Target constitutes close to 23 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The latest report Cyclin Dependent Kinase 4 - Pipeline Review, H2 2017, outlays comprehensive information on the Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition. Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 3, 1, 1, 12 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Genito Urinary System And Sex Hormones and Toxicology which include indications Breast Cancer, Mantle Cell Lymphoma, Metastatic Breast Cancer, Lymphoma, Non-Small Cell Lung Cancer, Colon Cancer, Colorectal Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Liposarcoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Oligodendroglioma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Recurrent Glioblastoma Multiforme (GBM), Solid Tumor, Thymic Carcinoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Renal Failure (ARF) (Acute Kidney Injury), Anaplastic Oligoastrocytoma, Astrocytoma, Bacterial Infections, Brain Tumor, Chemotherapy Induced Myelosuppression, Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Duodenal Cancer, Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Epstein-Barr Virus (HHV-4) Infections, Fallopian Tube Cancer, Gastric Cancer, Germ Cell Tumors, Glioblastoma Multiforme (GBM), Glioma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Leukemias, Melanoma, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Colorectal Cancer, Metastatic Ovarian Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Myelosuppression, Neuroblastoma, Neuroendocrine Tumors, Peritoneal Cancer, Primary CNS Lymphoma, Prostate Cancer, Rheumatoid Arthritis, Small-Cell Lung Cancer and Squamous Non-Small Cell Lung Cancer.

Furthermore, this report also reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
  • The report reviews Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Overview
    • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
    • Beta Pharma Inc
    • Eli Lilly and Co
    • G1 Therapeutics Inc
    • Jiangsu Hengrui Medicine Co Ltd
    • MEI Pharma Inc
    • Novartis AG
    • Onconova Therapeutics Inc
    • Pfizer Inc
    • Sihuan Pharmaceutical Holdings Group Ltd
    • Teijin Pharma Ltd
    • Tiziana Life Sciences Plc
    • ViroStatics srl
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Drug Profiles
    • abemaciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BPI-1178 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-1748 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-1T100182 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-1T100183 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-1T101551 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-1T38 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GZ-381 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HEC-80797 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • milciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ON-123300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palbociclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ribociclib succinate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHR-6390 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK4 and CDK6 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target Cdk2, Cdk4, Cdk6, Cyclin D1, Cyclin B1, Cdc2, p53 and p16 for Bacterial Infections and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRX-3177 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trilaciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • voruciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VS-2370 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XZP-3287 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Dormant Products
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Discontinued Products
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 16, 2017: Onco360 Selected for VERZENIO Limited Distribution Pharmacy Network
      • Oct 12, 2017: FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio (abemaciclib) as Initial Treatment of Advanced Breast Cancer
      • Oct 10, 2017: Diplomat Selected to Dispense VERZENIO for Breast Cancer
      • Oct 10, 2017: Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer
      • Oct 10, 2017: VERZENIO (abemaciclib) Approved for Treatment of Metastatic Breast Cancer, Available for Order at Biologics
      • Oct 06, 2017: Lilly MONARCH 3 Study Published In Journal Of Clinical Oncology Demonstrates Benefit Of Verzenio (Abemaciclib) Plus NSAI In Advanced Breast Cancer
      • Oct 04, 2017: Lilly Receives U.S. FDA Approval Of Verzenio (Abemaciclib)
      • Sep 28, 2017: FDA approves new treatment for certain advanced or metastatic breast cancers
      • Aug 30, 2017: CFDA Granted Approval of Phase I-III Clinical Trials for Birociclib, an Internally Developed Innovative Patented New Drug
      • Aug 29, 2017: New Phase 3 Data for Abemaciclib Presented at ESMO 2017 Congress
      • Aug 24, 2017: Novartis Kisqali (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
      • Aug 22, 2017: Alliance Foundation Trials Opens Global Trial Investigating First-In-Class Palbociclib In HR+, HER2 Metastatic Breast Cancer
      • Aug 14, 2017: Potential Treatment for Brain Cancer as Drug Shrinks Tumors
      • Jul 19, 2017: Tiziana Life Sciences Announces Initiation of a Phase IIa Clinical Trial with Milciclib in Patients with Hepatocellular Carcinoma
      • Jul 12, 2017: CFDA Granted Approval of Phase I-III Clinical Trials for Birociclib, an Internally Developed Innovative Patented New Drug
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Beta Pharma Inc, H2 2017
  • Pipeline by Eli Lilly and Co, H2 2017
  • Pipeline by G1 Therapeutics Inc, H2 2017
  • Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
  • Pipeline by MEI Pharma Inc, H2 2017
  • Pipeline by Novartis AG, H2 2017
  • Pipeline by Onconova Therapeutics Inc, H2 2017
  • Pipeline by Pfizer Inc, H2 2017
  • Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, H2 2017
  • Pipeline by Teijin Pharma Ltd, H2 2017
  • Pipeline by Tiziana Life Sciences Plc, H2 2017
  • Pipeline by ViroStatics srl, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
Back to Top